Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of P-BCMA-101 in multiple myeloma
NCT03741127Phase 1Active, not recruiting
- Sponsor
- Poseida Therapeutics
- Start
- Oct 2018
- Primary completion
- Aug 2032
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of P-BCMA-101 in multiple myeloma (MM), sponsored by Poseida Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 15 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
P-BCMA-101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03741127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03741127.